Home » Posts tagged with » China
AstraZeneca scores Chinese approval for heart failure therapy Forxiga

AstraZeneca scores Chinese approval for heart failure therapy Forxiga

AstraZeneca said that Forxiga (dapagliflozin) has secured approval in China for its use in the reduction of the risk of cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults having heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). The approval for the sodium-glucose co-transporter 2 inhibitor (SGLT2 inhibitor) from the Chinese […]

Thermo Fisher, JW Therapeutics sign CAR-T partnership in China

Thermo Fisher Scientific has signed an agreement with Chinese cell therapy company JW Therapeutics to provide the latter non-exclusive commercial access to its Gibco CTS Dynabeads CD3/CD28. The agreement will facilitate the clinical development and commercial manufacturing of CAR-T therapies in China, which includes JW Therapeutics’ lead product – relmacabtagene autoleucel (relma-cel). Relma-cel is an […]

Continue reading …
Amgen gets breakthrough therapy status for sotorasib in China

Amgen said that sotorasib, an investigational KRASG12C inhibitor, has been given breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. The Chinese breakthrough therapy designation for sotorasib is for the treatment of patients having KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer […]

Continue reading …
ADB grants loan to Jointown Pharmaceutical for expanding pharma distribution network in China

The Asian Development Bank (ADB) has agreed to provide a loan of up to €30 million ($37 million) to Jointown Pharmaceutical Group for expanding pharmaceutical distribution facilities in the China (PRC). The loan will be used towards the construction and expansion of Jointown Pharmaceutical’s pharma distribution facilities in Haikou, Tangshan, and Nanjing. The three facilities […]

Continue reading …
Antengene gets NMPA nod for eltanexor phase 1/2 clinical trial in myelodysplastic syndrome

Antengene has been given approval from China’s National Medical Products Administration (NMPA) for a phase 1/2 clinical trial of ATG-016 (eltanexor) in myelodysplastic syndrome (MDS). The Chinese biopharma company will enroll patients having intermediate and higher risk myelodysplastic syndrome as determined by the Revised International Prognostic Scoring System (IPSS-R) after the failure of hypomethylating agents […]

Continue reading …
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]

Continue reading …
Chinese biotech company InventisBio raises $147m in Series D round

InventisBio, a Chinese biotech company focused on small molecule drugs, has raised $147 million in a Series D funding round. The funding round of the clinical stage company was led by Hillhouse Capital affiliate GL Ventures. Other new investors are Qiming Venture Partners, Janchor, Matrix Partner China, AIHC Capital, Dyee Capital, and E Fund Capital […]

Continue reading …
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia

SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug Administration as an anti-seizure medication (ASM) under the brand name XCOPRI for the treatment of partial-onset seizures in adults. (Read here […]

Continue reading …
Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt

Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed Tyvyt (sintilimab injection), an approved blood cancer drug in China. The expanded deal gives the US pharma giant the rights to Tyvyt or geographies outside of China. Innovent Biologics and […]

Continue reading …
G42 Healthcare begins phase 3 trial of Sinopharm COVID-19 inactivated vaccine candidate in UAE

Sinopharm COVID-19 inactivated vaccine candidate : Chinese vaccine manufacturer Sinopharm CNBG has launched a phase 3 trial of its COVID-19 inactivated vaccine candidate, in collaboration with G42 Healthcare, in the UAE. The vaccine developer had found success with the phase 1 and phase 2 clinical trials of the coronavirus vaccine candidate in China. Its vaccine […]

Continue reading …
Page 1 of 512345